Artal Group S.A. raised its stake in Intellia Therapeutics Inc (NASDAQ:NTLA) by 42.9% during the fourth quarter, Holdings Channel reports. The fund owned 250,000 shares of the company’s stock after buying an additional 75,000 shares during the period. Artal Group S.A.’s holdings in Intellia Therapeutics were worth $4,805,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Intellia Therapeutics by 1.9% during the 4th quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock valued at $32,885,000 after buying an additional 31,662 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after buying an additional 92,580 shares in the last quarter. GMT Capital Corp purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at approximately $8,214,000. Granahan Investment Management Inc. MA lifted its stake in shares of Intellia Therapeutics by 7.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock valued at $7,111,000 after buying an additional 18,784 shares in the last quarter. Finally, Ark Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 118.9% during the 2nd quarter. Ark Investment Management LLC now owns 174,810 shares of the company’s stock valued at $2,797,000 after buying an additional 94,960 shares in the last quarter. Hedge funds and other institutional investors own 48.11% of the company’s stock.
Shares of Intellia Therapeutics Inc (NASDAQ NTLA) opened at $25.03 on Friday. The firm has a market cap of $1,040.00 and a P/E ratio of -16.15. Intellia Therapeutics Inc has a twelve month low of $11.15 and a twelve month high of $33.34.
In related news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,521,928 shares of company stock worth $51,883,434 in the last ninety days. 12.80% of the stock is currently owned by insiders.
WARNING: This piece of content was first posted by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2018/02/18/intellia-therapeutics-inc-ntla-shares-bought-by-artal-group-s-a.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.